#$%^&*AU2019257368A120191114.pdf#####ABSTRACT This invention relates to sustained release dosage forms comprising {f-1-[3fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-y1-3- [4-(7H-pyrrolo[2,3d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof, and doses and methods related thereto.7/12 FIG. 4(a) m 5 420 4. E o-2 0 20 40 60 80 Day -0- Placebo -a- 100 mgBID -+-200 mgBID -0- 300 mg QD -- 600 mg QD8/12 FIG. 4(b) 4- 13 02 01 0 (0 0 E + 0 ~ w -20I + o 500 1000 150 Cavg (nM) o Placebo A 100mgBID + 200 mg BID o 300 mg QD a 600 mg QD
